Roche Signed Licensing Deal for Obesity Drug
The pharmaceutical giant secured rights to an investigational RNAi drug candidate to expand its weight-loss portfolio.
Updated on Oct. 13, 2026 in Weight Loss
Live Poll
Do you trust that new pharmaceutical obesity treatments will improve long-term public health?
Roche has entered into a licensing agreement with Rona Therapeutics valued at up to $1.16 billion. The deal grants Roche access to an investigational RNAi drug candidate that targets activin receptor-like kinase 7 for potential obesity treatment.
Why it matters
By acquiring this candidate, Roche seeks to challenge the current market dominance held by Eli Lilly and Novo Nordisk. The company is actively expanding its footprint in the obesity space following mid-stage trial data reported earlier this year.
Rona Therapeutics will receive an initial payment of $100 million and is eligible for up to $1.06 billion in additional milestone payments. The contract also includes tiered royalties on future global net sales of the drug candidate.
The players
Roche
Roche is a multinational healthcare company based in Switzerland that operates in the pharmaceuticals and diagnostics sectors.
Rona Therapeutics
Rona Therapeutics is a biotechnology company focused on the development of RNAi-based therapies.
Eli Lilly
Eli Lilly is a major pharmaceutical firm known for developing widely used medications for the treatment of diabetes and obesity.
Novo Nordisk
Novo Nordisk is a global pharmaceutical company specializing in diabetes care and weight management treatments.
The details
The partnership focuses on a drug candidate targeting activin receptor-like kinase 7, a move that complements Roche's existing efforts in metabolic health. This deal follows the company's report of mid-stage trial data for its other obesity candidate, enicepatide, in September 2026.
Timeline
In September 2026, Roche reported mid-stage data for enicepatide.
On October 13, 2026, the companies announced the licensing agreement.
Health Landscape
This agreement reflects the broader pharmaceutical industry trend of securing novel RNAi drug candidates to compete in the growing global market for obesity treatments. It marks a significant shift in Roche's R&D focus as the company attempts to challenge established market leaders.
Patients currently seeking weight-loss treatments may eventually gain access to new therapeutic options if the drug successfully progresses through clinical trials. However, the timeline for potential market availability remains dependent on future regulatory and clinical milestones.
The takeaway
The move underscores the high investment stakes currently driving innovation in the metabolic disease sector. Investors and healthcare observers should watch for further clinical updates regarding this new partnership in the coming years.
Further reading
For more information on current developments in the field, visit the Weight Loss section.
Live Poll
Do you trust that new pharmaceutical obesity treatments will improve long-term public health?
